Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shakeel Modak

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Journal of Pediatric Surgery|May 4, 2005
Results of multimodal treatment for desmoplastic small round cell tumorsDave R Lal, Wendy T Su, Suzanne L Wolden, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2023
Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal DiseaseNeeta Pandit-Taskar, Milan Grkovski, Pat B Zanzonico, et al.
Pediatric Blood & Cancer|January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Biodistribution and Radiation Dosimetry of Intraperitoneally Administered <sup>124</sup>I-Omburtamab in Patients with Desmoplastic Small Round Cell TumorsMilan Grkovski, Shakeel Modak, Pat B Zanzonico, et al.
International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.
Pediatric Blood & Cancer|January 17, 2016
Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined RoomsBae P Chu, Christopher Horan, Ellen Basu, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Journal of Pediatric Surgery|May 4, 2005
Results of multimodal treatment for desmoplastic small round cell tumorsDave R Lal, Wendy T Su, Suzanne L Wolden, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2023
Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal DiseaseNeeta Pandit-Taskar, Milan Grkovski, Pat B Zanzonico, et al.
Pediatric Blood & Cancer|January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.
International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2021
Biodistribution and Radiation Dosimetry of Intraperitoneally Administered <sup>124</sup>I-Omburtamab in Patients with Desmoplastic Small Round Cell TumorsMilan Grkovski, Shakeel Modak, Pat B Zanzonico, et al.
International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.
Pediatric Blood & Cancer|January 17, 2016
Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined RoomsBae P Chu, Christopher Horan, Ellen Basu, et al.
Oncoimmunology|July 4, 2015
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II studyBrian H Kushner, Irina Ostrovnaya, Irene Y Cheung, et al.
Pageof 14